Aplus Radiopharmaceuticals is categorized under Research and Development Laboratories in Philadelphia, PA and active since 2011.
Aplus Radiopharmaceuticals was established in 2011, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Research and Development Laboratories business, which does work in the B2B market, and is classified as a Research and Development Laboratories, under code number 541712 by the NAICS.
If you are seeking more information, feel free to contact Hank Kung at the company’s single location by writing to 3160 Chestnut St # 200, Philadelphia, Pennsylvania PA 19104 or by phoning (215) 662-3096. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Aplus Radiopharmaceuticals |
| Contact Person: | Hank Kung |
| Address: | 3160 Chestnut St # 200, Philadelphia, Pennsylvania 19104 |
| Phone Number: | (215) 662-3096 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2011 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Research and Development Laboratories |
| SIC Code: | 8731 |
| NAICS Code: | 541712 |
| Share This Business: |
Aplus Radiopharmaceuticals was started in 2011 to provide professional Research and Development Laboratories under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Hank Kung for inquiries that concern Aplus Radiopharmaceuticals by calling the company number (215) 662-3096, as your correspondence is most welcome. Additionally, the physical location of the single location of Aplus Radiopharmaceuticals can be found at the coordinates 39.953553,-75.18659 as well as the street address 3160 Chestnut St # 200 in Philadelphia, Pennsylvania 19104.
For its online presence, you may visit Aplus Radiopharmaceuticals’s website at and engage with its social media outlets through on Twitter and on Facebook.